Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways
James A. McCubrey(East Carolina University), Alberto M. Martelli(University of Bologna), Franca Stivala(University of Catania), Christian Kempf(East Carolina University), Stephen L. Abrams(East Carolina University), Massimo Libra(University of Catania), Lucio Cocco(University of Bologna), Graziella Malaponte(University of Catania), Sanja Mijatović(University of Belgrade), Melchiorre Cervello(Foundation for Biomedical Research), Giuseppe Montalto(University of Palermo), Danijela Maksimović‐Ivanić(Institute for Biological Research “Siniša Stanković”), Ferdinando Nicoletti(University of Catania), Jörg Bäsecke(University of Göttingen), Linda S. Steelman(East Carolina University), William H. Chappell(University of North Carolina at Chapel Hill)
Cited by 171
Related Papers
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
|Frontiers in Pharmacology|2018|878
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
GSK-3 as potential target for therapeutic intervention in cancer
|Oncotarget|2014|508